SLU-PP-332 (Research Reagent Capsules)
$69.00
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptor (ERR) family, designed strictly for laboratory investigation of nuclear receptor-mediated metabolic gene programs, mitochondrial biogenesis pathways, and oxidative phosphorylation dynamics.
This compound activates ERRα, ERRβ, and ERRγ isoforms at nanomolar concentrations in cell-based reporter assay systems. It is supplied as a research-grade reference standard in capsule format for convenient laboratory handling and accurate mass measurement. Not for consumption, parenteral administration, or any application outside a controlled laboratory setting
1000 in stock
SLU-PP-332 ERR Agonist Research Compound
Pan-ERR Agonist | Synthetic Hydrazide | C18H14N2O2 | CAS 303760-60-3
FOR RESEARCH USE ONLY. Not intended for consumption, parenteral administration, therapeutic, or diagnostic application of any kind. For laboratory and preclinical research exclusively. Not a drug, dietary supplement, food, or cosmetic product.
TECHNICAL SPECIFICATIONS
| Property | Data |
|---|---|
| Product Reference | SLU-PP-332 ERR Agonist Research Compound |
| Chemical Class | Synthetic Hydrazide — Nuclear Receptor Modulator |
| IUPAC Name | 4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide |
| Physical Format | Capsule-Encapsulated Research Reagent — Sealed Container |
| Molecular Formula | C18H14N2O2 |
| Molecular Mass | 290.32 g/mol |
| CAS Registry | 303760-60-3 |
| PubChem CID | 5338394 |
| Receptor Target | ERRα / ERRβ / ERRγ (Pan-Agonist) |
| ERRα EC50 | ~98 nM (cell-based reporter assay) |
| ERRβ EC50 | ~230 nM (cell-based reporter assay) |
| ERRγ EC50 | ~430 nM (cell-based reporter assay) |
| Analytical Purity | ≥98% (RP-HPLC) |
| Identity Confirmation | LC-MS — Molecular ion verified |
| Solubility | DMSO (soluble), aqueous buffer (limited) |
| Storage | -20°C, desiccated, light-protected |
| Regulatory Class | Research Use Only (RUO) — Not for administration to living organisms |
Disclaimer : For Research Use Only (RUO). Not for human use.
Product Overview
This product comprises a synthetic hydrazide-class nuclear receptor modulator known as SLU-PP-332. It is classified as a pan-agonist of the estrogen-related receptor family — a group of orphan nuclear receptors (ERRα/NR3B1, ERRβ/NR3B2, ERRγ/NR3B3) that regulate transcriptional programs governing mitochondrial function, fatty-acid oxidation gene expression, and oxidative metabolism in high-energy-demand tissues.
Unlike conventional receptor ligands limited to a single isoform endpoint, SLU-PP-332’s pan-agonist architecture enables researchers to study how simultaneous activation of all three ERR isoforms modulates interconnected metabolic gene networks — making it uniquely valuable for comprehensive energy metabolism and mitochondrial biology research design.
Research Mechanism -2026 Laboratory Applications
- 1. ERRα Transcriptional Activation & Metabolic Gene Programs
Investigating how SLU-PP-332 binds the ERRα ligand-binding domain (EC50 ~98 nM) to activate transcription at ERR response elements, upregulating genes involved in fatty-acid oxidation, tricarboxylic acid cycle flux, and oxidative phosphorylation in skeletal muscle cell-line models. - 2. Mitochondrial Biogenesis & Respiration Quantification
Measuring how ERR activation increases maximal mitochondrial respiration capacity, mitochondrial DNA copy number, and expression of oxidative phosphorylation complex proteins (NDUFB8, ATP5A, cytochrome c) in C2C12 myoblast culture systems using Seahorse XF analyzer and qPCR endpoints. - 3. Exercise-Responsive Transcription Factor Dynamics
Studying how SLU-PP-332 transiently induces expression of genes normally upregulated during aerobic exercise (DDIT4, SLC25A25, Period 1/2, FOXO1) with peak expression at 1–3 hours and return to baseline by six hours, mirroring natural exercise-responsive kinetics in cell-based assay models. - 4. ERR Isoform-Specific Pathway Dissection
Quantifying differential contributions of ERRα (EC50 ~98 nM), ERRβ (EC50 ~230 nM), and ERRγ (EC50 ~430 nM) to tissue-specific metabolic gene activation using isoform-selective knockout models and reporter assay systems in skeletal muscle versus cardiac tissue contexts. - 5. Oxidative Phosphorylation Complex Quantification
Measuring succinate dehydrogenase activity changes, OXPHOS protein panel expression, and electron transport chain efficiency following ERR pan-agonist exposure in mitochondrial isolation and intact cell respiration assays.
MOLECULAR STRUCTURE
SLU-PP-332 — PubChem CID 5338394
SLU-PP-332 (4-hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide) is a synthetic small molecule with molecular formula C18H14N2O2 and molecular mass 290.32 g/mol. The compound features a hydrazide linkage connecting a 4-hydroxybenzene ring to a naphthalene moiety, creating a planar aromatic scaffold capable of π-π stacking interactions with amino acid residues in the ERR ligand-binding domain.
This structural modification from the earlier ERR agonist GSK4716 — replacing the isopropylphenyl group with a naphthalene ring — improved ERRα potency approximately 50-fold. The compound was developed at Saint Louis University (SLU) and is catalogued under PubChem CID 5338394 and CAS 303760-60-3.
Receptor Binding Profile — Cell-Based Reporter Assay Data
| ERR Isoform | EC50 (nM) | Primary Research Endpoint |
|---|---|---|
| ERRα (NR3B1) | ~98 nM | Fatty-acid oxidation gene programs, metabolic transcription |
| ERRβ (NR3B2) | ~230 nM | Energy metabolism co-regulation, tissue-specific modulation |
| ERRγ (NR3B3) | ~430 nM | Cardiac tissue gene activation, mitochondrial dynamics |
COMPARATIVE RESEARCH CONTEXT — 2026 ERR Agonist Research Landscape
| Feature | SLU-PP-332 | GSK4716 | DY131 | XCT790 (Inverse) |
|---|---|---|---|---|
| Receptor Profile | Pan-ERR (α/β/γ) | ERRα/β | ERRβ/γ | ERRα Inverse Agonist |
| ERRα Potency | ~98 nM | ~4,900 nM | Low affinity | Inverse agonist |
| ERRβ Potency | ~230 nM | Active | ~370 nM | No activity |
| ERRγ Potency | ~430 nM | No activity | ~920 nM | No activity |
| Pan-Agonist Coverage | ■ All 3 isoforms | ■ 2 isoforms | ■ 2 isoforms | ■ Inverse |
| Structural Class | Hydrazide | Phenylisoxazole | Stilbene | Thiadiazoleacrylamide |
| Preclinical Studies | ■ Extensive | ■ Moderate | ■ Moderate | ■ Moderate |
KEY DIFFERENTIATOR: SLU-PP-332 is the only ERR agonist tool compound that activates all three ERR isoforms (α, β, γ) simultaneously at nanomolar potency. GSK4716 lacks ERRγ activity, DY131 has weak ERRα engagement, and XCT790 functions as an inverse agonist. For researchers studying pan-ERR metabolic gene network activation, SLU-PP-332 remains the reference standard compound in the 2026 reagent landscape.
WHY SOURCE FROM PROFOUND AMINOS
1. Molecular Identity Verification via LC-MS
Standard purity testing confirms percentage composition but does not confirm molecular identity. We verify SLU-PP-332 identity via liquid chromatography-mass spectrometry (LC-MS), confirming the expected molecular ion at m/z 290.32 and fragmentation pattern consistent with the hydrazide scaffold before batch release. Purity without identity confirmation is an incomplete quality standard.
2. Capsule-Format Precision — The Laboratory Handling Advantage
SLU-PP-332 is supplied in pre-measured capsule format to enable accurate mass transfer in laboratory settings without requiring analytical balance weighing of loose powder for each experiment. Each capsule contains a fixed, verified quantity of compound — reducing preparation variability and improving experimental reproducibility across assay replicates.
3. Cold-Chain Integrity — USA Domestic Shipping
Research-grade compounds are thermally sensitive. International sourcing introduces uncontrolled temperature excursions during customs transit. SLU-PP-332 ships exclusively within the USA via a monitored cold-chain logistics protocol — from a climate-controlled facility directly to your research address — eliminating degradation risks inherent to overseas sourcing.
REGULATORY & COMPLIANCE STATEMENT (RUO)
| Classification Detail | Description |
|---|---|
| Regulatory Status | Research Use Only (RUO) — U.S. Federal Regulatory Framework |
| FDA Status | Not approved. No FDA marketing authorisation in any indication. No NDA/ANDA filed. |
| Not a Drug | Not evaluated by FDA for safety or efficacy in any application. |
| Not a Supplement | Not a dietary supplement, nutraceutical, or consumer product. |
| Not a Cosmetic | Not intended for topical, dermal, or cosmetic application. |
| Chemical Reference | Supplied solely for laboratory testing and preclinical investigation. |
| PPE Required | Gloves, lab coat, protective eyewear during handling. |
| CAS Registry | 303760-60-3 |
| PubChem CID | 5338394 |
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL APPLICATION.
STRICT PROHIBITION: Promoting, distributing, or using this research compound for any application involving administration to living organisms is strictly prohibited and constitutes a violation of U.S. federal law. This product is not manufactured, labeled, or intended for any pharmaceutical, therapeutic, or clinical application. FDA enforcement actions in 2024–2026 have established that RUO disclaimers do not protect sellers when overall marketing content indicates intended human use.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
Q1: Is SLU-PP-332 intended for consumption or administration?
No. SLU-PP-332 is strictly classified as a Research Use Only (RUO) compound. It is not approved, labeled, or intended for consumption, parenteral administration, therapeutic use, or any diagnostic application. It is not a drug, dietary supplement, food, or cosmetic. Purchase confirms agreement to institutional laboratory research use only.
Q2: What are estrogen-related receptors (ERRs)?
Estrogen-related receptors are a family of orphan nuclear receptors (ERRα/NR3B1, ERRβ/NR3B2, ERRγ/NR3B3) that regulate transcriptional programs governing mitochondrial biogenesis, fatty-acid oxidation, oxidative phosphorylation, and energy homeostasis. Despite their name, ERRs do not bind estrogen and function independently of estrogen receptor signalling. They are constitutively active transcription factors studied extensively in metabolic research.
Q3: What does pan-ERR agonist mean?
Pan-ERR agonist means SLU-PP-332 activates all three ERR isoforms (α, β, γ) simultaneously, as opposed to isoform-selective compounds that target only one or two receptors. This enables researchers to study how coordinated activation of the entire ERR family modulates interconnected metabolic gene networks in cell-based assay systems.
Q4: Why is SLU-PP-332 supplied in capsule format?
Capsule encapsulation provides pre-measured quantities for convenient laboratory handling. Capsules serve as inert containers for transporting the research reagent and enabling accurate mass transfer without requiring analytical balance weighing of loose powder for each individual experiment. Capsule format is not a dosage form and does not indicate suitability for ingestion.
Q5: What is the FDA regulatory status of SLU-PP-332?
SLU-PP-332 has no FDA approval as a drug, dietary supplement, or any finished pharmaceutical product. No FDA marketing authorisation exists for SLU-PP-332 in any indication as of April 2026. Commercial biochemical suppliers (Tocris, MedChemExpress, Focus Biomolecules) classify it as a laboratory research reagent. In 2024–2026, FDA issued multiple warning letters to online vendors selling pharmacologically active research compounds with implied human-use claims, establishing that RUO labels do not protect sellers if overall marketing indicates intended use in humans.
Q6: Does SLU-PP-332 have published clinical trial data?
No. SLU-PP-332 has no published human clinical trials as of April 2026. All published research is preclinical — limited to cell-based reporter assays, C2C12 myoblast culture models, and rodent metabolic studies. Academic reviews highlight promising preclinical findings for mitochondrial biogenesis and metabolic gene activation but identify the absence of clinical data and potential off-target effects as major barriers to any future therapeutic development.
Q7: What preclinical research endpoints are studied with SLU-PP-332?
Published preclinical endpoints include: maximal mitochondrial respiration capacity (Seahorse XF), mitochondrial DNA copy number (qPCR), oxidative phosphorylation protein expression (Western blot), succinate dehydrogenase activity, exercise-responsive gene induction kinetics (DDIT4, SLC25A25, PER1/2, FOXO1), respiratory exchange ratio measurements, and ERR isoform-specific transcriptional activation in cell-based luciferase reporter systems.
Q8: Can SLU-PP-332 be used outside a controlled laboratory research setting?
Absolutely not. This compound is classified strictly for laboratory investigation only. Any non-laboratory use — including personal, consumer, or wellness applications — violates our Terms of Service and will result in immediate order cancellation. Refer to our Terms & Conditions for full compliance requirements.
Q9: Do you provide a COA for every batch?
Yes. Every SLU-PP-332 batch includes a Certificate of Analysis verifying purity via RP-HPLC, identity confirmation via LC-MS, lot number, and manufacturing date. Available for download per batch from our COA portal.
Q10: What is the structural relationship between SLU-PP-332 and GSK4716?
SLU-PP-332 was developed at Saint Louis University as a structural optimisation of the earlier ERR agonist GSK4716. The key modification involved replacing GSK4716’s isopropylphenyl group with a naphthalene ring, which improved ERRα potency approximately 50-fold and extended agonist activity across all three ERR isoforms. The hydrazide linkage connecting the 4-hydroxybenzene to the naphthalene moiety creates the planar aromatic scaffold responsible for high-affinity receptor binding.
KEY REFERENCES — PubMed / PubChem Verified
| # | Citation | Relevance |
|---|---|---|
| 1 | Billon C et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Clin Invest 2023 (PMC cited by 38) | SLU-PP-332 preclinical metabolic study — primary reference |
| 2 | Patch RJ et al. SLU-PP-332 and Related ERRα Agonists. Curr Top Med Chem 2024 | ERR agonist structural optimisation review |
| 3 | PubChem CID 5338394 — SLU-PP-332 Compound Record | Chemical identity, structure, computed properties |
| 4 | Tocris Bioscience — SLU-PP-332 Product Datasheet | Commercial reagent specification reference |
| 5 | MedChemExpress — SLU-PP-332 ERR Pan-Agonist | Biochemical supplier classification |
| 6 | FDA Warning Letter — Summit Research Peptides — December 2024 | RUO enforcement precedent |
| 7 | FDA Warning Letter — USApeptide.com — February 2025 (MARCS-CMS 696885) | Intended use determination via web content |
| 8 | FDA Intent to Act Against Non-FDA-Approved Products — February 2026 | Enforcement environment escalation |
| 9 | Google Ads Policy — Unapproved Substances — 2026 | Platform advertising compliance |
| 10 | Google Search Quality Rater Guidelines — YMYL/E-E-A-T — 2026 | Content quality framework |
RESEARCH USE ONLY — NOT FOR HUMAN USE — NOT FOR ANIMAL USE
All content for scientific education and non-clinical laboratory reference only | No medical claims made or implied
| Strength |
500 mcg |
|---|---|
| Count |
100 Capsules |
DISCLAIMER:
- Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited. They must also not be misbranded, misused, or mislabeled, or used for anything other than research and scientific investigation.
- All the products you see on the website are being sold in a lyophilized powder state (freeze-dried), in a sealed sterile vial; and should be reconstituted.
The product’s label clearly states the amount of product a vial contains; some products are offered in different variations. - The products we are selling come in a sealed vial but require additional lab equipment for proper testing.
- Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.
Frequently bought together: Cerebrolysin, BPC-157 Stable (Arg-Salt Capsules), LIPO-B
Related products
